E-therapeutics Regulatory News (ETX)

e-Therapeutics plc

('e-Therapeutics' or 'the Company')

Additional listing

18 June 2014, Oxford and Newcastle, UK: e-Therapeutics plc (AIM: ETX), the drug discovery and development company, announces that on 18 June 2015 the Company issued 92,730 ordinary shares of 0.1p each in the Company in order to satisfy the exercise of certain options by an employee.

Application has been made to admit the new ordinary shares to trading on AIM and dealings in the new ordinary shares are expected to commence on 23 June 2015. Following admission the number of Ordinary Shares in the Company in issue will be 264,455,551. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, e-Therapeutics plc under the Financial Conduct Authority's Disclosure and Transparency Rules.

Contacts:

e-Therapeutics plc

Steve Medlicott, Finance Director

Tel: +44 (0) 1993 883125

www.etherapeutics.co.uk 

N+1 Singer

Aubrey Powell / Jen Boorer

Tel: +44 (0)207 496 3000

www.n1singer.com 

About e-Therapeutics plc

e-Therapeutics is a drug discovery and development company with a proprietary platform in network pharmacology, an innovative approach to drug discovery based on advances in network science and chemical biology. e-Therapeutics' platform is generating more potent, selective and diverse molecules at much higher yields than is reported for conventional drug discovery. The Company's discovery and development activity addresses age-related diseases, including cancer and central nervous system disorders, and it is fully funded to advance its programme into 2019, including phase II clinical data and multiple regulatory submissions.

e-Therapeutics has a phase IIb clinical stage drug candidate for major depressive disorder, ETS6103. It has a phase Ib clinical stage candidate in hepatocellular and pancreatic cancer, ETS2101. The company has a variety of preclinical stage assets, including ETX1153c, a functionally resistance-less antibiotic; ETS2300, potent telomerase inhibition in anti-cancer; ETS3100, potent small molecule anti-TNFα; ETS2400, potent Hedgehog pathway inhibition; and ETS6200, in neuroprotection.

e-Therapeutics is based at sites in Oxford and Newcastle, UK. For more information about the Company, please visit www.etherapeutics.co.uk.